Evaluation of the respiratory syncytial virus G-directed neutralizing antibody response in the human airway epithelial cell model
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Sanofi Pasteur
This publication has 22 references indexed in Scilit:
- Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial CulturesPLOS Pathogens, 2015
- An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c miceVirology, 2015
- CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent MannerPLOS ONE, 2015
- Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus InfectionPediatrics, 2014
- A Respiratory Syncytial Virus (RSV) Anti-G Protein F(ab′)2Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-Infected BALB/c MiceJournal of Virology, 2013
- The Comparative Genomics of Human Respiratory Syncytial Virus Subgroups A and B: Genetic Variability and Molecular Evolutionary DynamicsJournal of Virology, 2013
- AF03, An Alternative Squalene Emulsion‐Based Vaccine Adjuvant Prepared by a Phase Inversion Temperature MethodJournal of Pharmaceutical Sciences, 2012
- Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected PatientsThe Journal of Immunology, 2009
- Role of complement in neutralization of respiratory syncytial virusJournal of Medical Virology, 2004
- The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins.Proceedings of the National Academy of Sciences, 1987